Novocure (NASDAQ: NVCR) reported Q3 EPS of ($2.09), versus ($1.45) reported last year. Revenue for the quarter came in at $8.95 million, versus $4.37 million reported last year.

Third Quarter 2015 Operating Statistics

• 354 prescriptions were received in the quarter, an increase of 149% versus the prior year quarter. These gains were achieved prior to FDA approval of Optune for newly diagnosed GBM.
• There were 468 active patients on Optune therapy at quarter end, an increase of 161% versus the prior year quarter. 408 of the active patients were in the US and 60 of the active patients were outside of the US, primarily in Europe.
• In the US, total cash payments of $19.7 million, net of indirect taxes, received during the nine months ended September 30, 2015 were recorded as revenues for Optune therapy provided to patients in the current and prior periods. These cash payments represent an average of approximately $14,500 for each month of use, net of indirect taxes.

For earnings history and earnings-related data on Novocure (NVCR) click here.